2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2286 Patterns of progression and salvage outcomes after BCMA-directed CAR T-cell therapy

Zhouning Lin, Luo Wang2, Shuyang Wang, MD3, Mingming Zhang, PhD4, Shan Fu5, Jingjing Feng6, Guoqing Wei7, Alex H. Zhang, Dr.8, He Huang, PhD9, Yongxian HU, MD10
1 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Shanghai YaKe Biotechnology Ltd., Shanghai, China
9 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has shown substantial activity in patients with relapsed/refractory multiple myeloma (R/R MM). However, disease progression remains a major clinical challenge. Post-progression disease patterns and outcomes after salvage therapy have not been well described, particularly in patients with extramedullary disease (EMD).

Methods

We retrospectively included 141 patients with R/R MM who received BCMA-directed CAR T-cell therapy between July 2018 and September 2023. Patients were classified according to baseline disease involvement as EMD, paraskeletal disease (PSD), or bone marrow-only disease (BM-only). Among patients who achieved a response after CAR T-cell therapy and subsequently developed disease progression, progression phenotype, first salvage treatment, post-progression progression-free survival (PFS2), and post-progression overall survival (OS2) were analyzed.

Results

Among 141 patients, 36, 29, and 76 had baseline EMD, PSD, and BM-only disease, respectively. Median PFS and OS for the overall cohort were 14.4 and 43.2 months. Median PFS was 7.6, 14.4, and 26.0 months in the EMD, PSD, and BM-only groups, respectively (P<0.001), and median OS was 16.5, 49.2, and 55.5 months, respectively (P<0.001).

Overall, 94 patients developed disease progression after an initial response. The median time from CAR T-cell infusion to progression was 12.4 months. Progression phenotype was evaluable in 82 patients. At progression, 42, 30, and 10 patients had EMD, PSD, and BM-only progression, respectively. Median PFS2 was 3.3, 4.5, and 16.4 months in these groups (P=0.041), and median OS2 was 8.8 months, 27.1 months, and not reached, respectively (P=0.0012).

Among patients with progression, 72 received active first salvage therapy, 6 received palliative/supportive care, and subsequent treatment information was unavailable in 16. First salvage therapy included chemotherapy in 16 patients, novel/targeted therapy in 27, second CAR T-cell therapy in 24, radiotherapy/local therapy in 3, and hematopoietic stem cell transplantation in 2.

Median PFS2 was 3.1, 3.7, and 8.3 months in the chemotherapy, novel/targeted therapy, and second CAR T-cell therapy groups, respectively (P=0.023). Median OS2 was 5.7, 7.2, and 48.2 months, respectively (P<0.001).

Among patients with EMD progression, 31 received one of the three major first salvage approaches. Chemotherapy, novel/targeted therapy, and second CAR T-cell therapy were used in 12, 10, and 9 patients, respectively. Median PFS2 was 3.4, 2.8, and 6.1 months (P=0.080), and median OS2 was 9.6, 5.2, and 20.1 months, respectively (P=0.101).

Conclusions

Patients who progressed after BCMA-directed CAR T-cell therapy had poor outcomes, particularly those with EMD progression. Second CAR T-cell therapy was associated with longer PFS2 and OS2 in the overall progression cohort, supporting cellular therapy sequencing as a potential salvage strategy after post-CAR T-cell relapse. Further studies are needed to define its role in patients with EMD progression.

Zhouning Lin: No relevant conflicts of interest to declare.